Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

ADC liker

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (1) ADC Linker (1) ADC Payload (1) Drug-Linker Conjugates for ADC (2) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (1) Biochemical Assay Reagents (2) Btk (1) c-Met/HGFR (1) DNA/RNA Synthesis (1) EGFR (1) Notch (1) PROTAC-Linker Conjugates for PAC (1) Topoisomerase (2)
By Research Areas:	Cancer (8) Inflammation/Immunology (1)
Click Chemistry:	Azide (2) Alkynes (1)

Inhibitors & Agonists

Inhibitory Antibodies

Click Chemistry

Targets Recommended: ADC Payload ADC Antibody Drug-Linker Conjugates for ADC ADC Linker

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99043

Rovalpituzumab 1 Publications Verification SC-0001	Notch	Cancer
Rovalpituzumab is a humanized monoclonal antibody against *delta-like* protein 3 (DLL3)*. Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC*), Rovalpituzumab Tesirine. Rovalpituzumab has activity against small cell lung cancer (SCLC) .

HY-171124

Tilatamig samrotecan AZD9592	Antibody-Drug Conjugates (ADCs) EGFR c-Met/HGFR Topoisomerase DNA/RNA Synthesis	Cancer
Tilatamig samrotecan (AZD9592) is an anti-EGFR/c-MET antibody-drug conjugate (ADC). Tilatamig samrotecan consists of an anti-EGFR/c-MET antibody with the drug-linker conjugate being AZ14170133 (HY-145399) (a topoisomerase I (TOP1i) inhibitor payload). Tilatamig samrotecan induces multiple DNA damage response pathway markers (like ATM, ATR, γH2AX). Tilatamig samrotecan selectively binds to EGFR and c-MET, delivering the cytotoxic payload. Tilatamig samrotecan exerts anti-tumor activity in vivo. Tilatamig samrotecan can be used for non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) research .

HY-126666

PNU-159682 carboxylic acid	ADC Payload	Inflammation/Immunology Cancer
PNU-159682 carboxylic acid (Compound 53) is a potent ADCs cytotoxin and encodes a member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily. PNU-159682 carboxylic acid has protein fold and diverse functions, such as cell adhesion, cell-cell signalling, glycoprotein turnover, and roles in inflammation and immune response .

HY-159072

Mal-Val-Ala-PAB-N(SO2Me)-Exatecan	Drug-Linker Conjugates for ADC	Cancer
Mal-Val-Ala-PAB-N(SO2Me)-Exatecan (Compound LE14) is a conjugate of an ADC toxin Exatecan (HY-13631) and a linker Mal-Val-Ala-PAB-N(SO2Me). Mal-Val-Ala-PAB-N(SO2Me)-Exatecan can be used for synthesis of ADC FZ-AD005. FZ-AD005 is a *delta-like* ligand 3 (DLL3, K_D*=58.3 pM) targeting ADC*, that exhibits antitumor efficacy against SCLC cancer .

HY-163099

P5(PEG24)-VC-PAB-Exatecan	Drug-Linker Conjugates for ADC Topoisomerase Apoptosis	Cancer
P5 (PEG24)-VC-PAB-Exatecan is a TOP1 inhibitor payload with antibody-conjugation-dependent activity. Conjugation of P5 (PEG24)-VC-PAB-Exatecan with Trastuzumab (HY-P9907) generates a DAR8 antibody-drug conjugate (ADCs) with antibody-like pharmacokinetic properties. P5 (PEG24)-VC-PAB-Exatecan induces S-phase and G2-M-phase cell cycle arrest, DNA damage and apoptosis in target-positive tumor cells, and releases damage-associated molecular patterns (DAMP) related to immunogenic cell death (ICD). The ADCs prepared from it exert bystander killing effects on non-target tumor cells. ADCs based on P5 (PEG24)-VC-PAB-Exatecan exhibit linker stability in vitro and in vivo, show in vivo efficacy, and can be used in research related to HER2-positive cancers .

HY-157763

Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1	PROTAC-Linker Conjugates for PAC Btk	Cancer
Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 is a cleavable linker-payload conjugate and cereblon-binding BTK bifunctional degrader. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 induces BTK degradation and exerts cytotoxic effects when delivered via CD79b monoclonal antibody. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1, when formulated as a CD79b antibody-drug conjugate, achieves sustained in vivo BTK degradation in tumor-bearing mice with reduced systemic payload exposure. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 can be used for the research of activated b-cell-like diffuse large b-cell lymphoma (ADC linker: (HY-130944); PROTAC: (HY-163295)) .

HY-P990896

FZ-A038	ADC Antibody	Cancer
FZ-A038 is a *delta-like* ligand 3 (DLL3*) targeted, humanized monoclonal antibody. FZ-A038 can be used for synthesis of DLL3 targeting ADC* FZ-AD005 (HY-164729) .

HY-151859

N3-Gly-Gly-OH	Biochemical Assay Reagents	Others
N3-Gly-Gly-Gly-OH is a click chemistry reagent containing an azide group. N3-Gly-Gly-OH undergoes copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing an alkyne group. N3-Gly-Gly-OH also undergoes strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups. N3-Gly-Gly-Gly-OH can be used to construct peptide-like ADC linkers via click chemistry .

HY-151859A

N3-Gly-Gly-OH (DCHA)	Biochemical Assay Reagents	Others
N3-Gly-Gly-OH DCHA is a click chemistry reagent containing an azide group. N3-Gly-Gly-OH DCHA undergoes copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing an alkyne group. N3-Gly-Gly-OH DCHA also undergoes strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups. N3-Gly-Gly-OH DCHA can be used to construct peptide-like ADC linkers via click chemistry .

HY-164929

PTAD-PEG8-azide	ADC Linker	Cancer
PTAD-PEG8-azide is a cleavable ADC linker containing an azide group. PTAD-PEG8-azide can be used in the synthesis of antibody-drug conjugates (ADCs).

Cat. No.	Product Name	Target	Research Area	Image

HY-P99043

Rovalpituzumab 1 Publications Verification SC-0001	Notch	Cancer
Rovalpituzumab is a humanized monoclonal antibody against *delta-like* protein 3 (DLL3)*. Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC*), Rovalpituzumab Tesirine. Rovalpituzumab has activity against small cell lung cancer (SCLC) .

HY-P990896

FZ-A038	ADC Antibody	Cancer
FZ-A038 is a *delta-like* ligand 3 (DLL3*) targeted, humanized monoclonal antibody. FZ-A038 can be used for synthesis of DLL3 targeting ADC* FZ-AD005 (HY-164729) .

Cat. No.	Product Name		Classification

HY-163099

P5(PEG24)-VC-PAB-Exatecan		Alkynes
P5 (PEG24)-VC-PAB-Exatecan is a TOP1 inhibitor payload with antibody-conjugation-dependent activity. Conjugation of P5 (PEG24)-VC-PAB-Exatecan with Trastuzumab (HY-P9907) generates a DAR8 antibody-drug conjugate (ADCs) with antibody-like pharmacokinetic properties. P5 (PEG24)-VC-PAB-Exatecan induces S-phase and G2-M-phase cell cycle arrest, DNA damage and apoptosis in target-positive tumor cells, and releases damage-associated molecular patterns (DAMP) related to immunogenic cell death (ICD). The ADCs prepared from it exert bystander killing effects on non-target tumor cells. ADCs based on P5 (PEG24)-VC-PAB-Exatecan exhibit linker stability in vitro and in vivo, show in vivo efficacy, and can be used in research related to HER2-positive cancers .

HY-151859

N3-Gly-Gly-OH		Azide
N3-Gly-Gly-Gly-OH is a click chemistry reagent containing an azide group. N3-Gly-Gly-OH undergoes copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing an alkyne group. N3-Gly-Gly-OH also undergoes strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups. N3-Gly-Gly-Gly-OH can be used to construct peptide-like ADC linkers via click chemistry .

HY-151859A

N3-Gly-Gly-OH (DCHA)		Azide
N3-Gly-Gly-OH DCHA is a click chemistry reagent containing an azide group. N3-Gly-Gly-OH DCHA undergoes copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing an alkyne group. N3-Gly-Gly-OH DCHA also undergoes strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups. N3-Gly-Gly-OH DCHA can be used to construct peptide-like ADC linkers via click chemistry .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.